» Articles » PMID: 19844890

Health-related Quality of Life in Dialysis Patients with HCV Infection

Overview
Date 2009 Oct 22
PMID 19844890
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Measuring the impact of chronic kidney disease (CKD) treatment on patient quality of life has become increasingly recognized as an important outcome measure. Despite improvements in the treatment of chronic kidney disease, health-related quality of life (HRQOL) is lower than in the general population. HRQOL measures, particularly the Physical Component Summary (PCS), have predictive validity for risk of both mortality and hospitalization in dialysis populations. For every 10-point lower PCS score, the relative risk (RR) of death increases by 29% (RR = 1.29; 95% CI = 1.23 to 1.35; p < 0.001) and the risk of hospitalization increases by 15% (RR = 1.15; 95% CI = 1.11 to 1.19, p < 0.001), according to the Dialysis Outcomes and Practice Patterns Study (DOPPS). Hepatitis C virus (HCV) infection remains prevalent among dialysis patients with a recent meta-analysis showing that anti-HCV seropositive status was an independent and significant risk factor for death in patients on maintenance dialysis. Seven studies with 11,589 unique patients on maintenance dialysis were identified; the summary estimate for adjusted relative risk (aRR) (all-cause mortality) was 1.34 with a 95% confidence interval (CI) of 1.13-1.59. In non-uremic populations HCV diminishes HRQOL, and individuals with HCV scored lower than controls across all scales of the short form 36 (SF-36). Patients achieving sustained virological responses (SVR) scored higher across all scales versus patients without SVR, especially in the physical health domains. Whether the adverse influence of HCV on survival in dialysis population is related to the negative impact of HCV on HRQOL requires further research. Information on HRQOL indices in patients with HCV on maintenance dialysis is extremely limited but the available evidence shows that HCV infection impairs HRQOL, especially in mental aspects, among patients on maintenance hemodialysis.

Citing Articles

Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study.

Czarnecka P, Czarnecka K, Tronina O, Baczkowska T, Wyczalkowska-Tomasik A, Durlik M J Clin Med. 2023; 12(10).

PMID: 37240622 PMC: 10219487. DOI: 10.3390/jcm12103513.


Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.

Ponnuvel S, Fletcher G, Anantharam R, Varughese S, David V, Abraham P PLoS One. 2021; 16(4):e0250263.

PMID: 33886631 PMC: 8061997. DOI: 10.1371/journal.pone.0250263.


Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents.

Reddy Y, Nunes D, Chitalia V, Gordon C, Francis J Hemodial Int. 2018; 22 Suppl 1:S53-S60.

PMID: 29694721 PMC: 6815878. DOI: 10.1111/hdi.12659.


Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.

Patel Y, Muir A Curr Hepatol Rep. 2017; 15(4):285-290.

PMID: 28584732 PMC: 5455785. DOI: 10.1007/s11901-016-0319-5.


Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan.

Hsu Y, Hung P, Muo C, Tsai W, Hsu C, Kao C Medicine (Baltimore). 2015; 94(47):e2113.

PMID: 26632730 PMC: 5058999. DOI: 10.1097/MD.0000000000002113.